Professor Jonathan Baell
Monash Institute of Pharmaceutical Sciences
Research Professor, Medicinal Chemistry.
Co-Director, Australian Translational Medicinal Chemistry Facility.
NHMRC Senior Research Fellow.
Phone:+61 3 9903 9044
Medicinal Chemistry is one of the most important sciences in the 21st century for the discovery of new drugs that are selective, potent and non-toxic in order to better treat diseases with unmet needs, from cancer to multiple sclerosis
Professor Jonathan Baell is interested in the discovery of new drugs to treat diseases with unmet needs. Currents interests are focused on infectious diseases such as malaria and tuberculosis, and trypanosomatid-mediated neglected diseases such as Sleeping Sickness and Chagas disease. A parallel theme is focused on anticancer drug discovery. This ranges from the discovery of novel epigenetic modulators for the treatment of acute myeloid leukaemia (AML) to chemical biology approaches to improving targeted delivery of cytotoxic anticancer agents. For earlier work in the area of ion channel-blocking multiple sclerosis drug discovery, Jonathan was awarded the Biota Medal, a National Award for medicinal chemistry excellence for early to mid-career researchers. Jonathan enjoys playing tennis and table tennis as well as occasional attempts at playing the piano.
Selected recent publications
Baell JB. Broad coverage of commercially available lead-like screening space with fewer than 350,000 Compounds. J. Chem. Inf. Model. 53 (2013) 39-55.
Lessene G, Czabotar P, Sleebs BE, Zobel K, Lowes KL, Adams JM, Baell JB, Colman PM, Deshayes K, Fairbrother WJ, Flygare JA, Gibbons P, Kersten WJA, Kulasegaram S, Moss RM, Parisot JP, Smith BJ, Street IP, Yang H, Huang DCS, Watson KG. Structure-guided design of a selective BCL-XL inhibitor. Nat. Chem. Biol. 9 (2013) 390-397.
Ferrins L, Rahmani R, Sykes ML,Jones A, Avery VM, Teston E, Almohaywi B, Yin J, Smith J, Hyland C, White KL; Ryan E, Campbell M, Charman SA, Kaiser M., Baell JB. 3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis Eur. J. Med. Chem. 66 (2013) 450-465.
Teguh SC, Klonis N, Duffy S, Lucantoni L, Avery VM, Hutton CA, Baell JB*, Tilley L*. Novel conjugated quinoline-indoles compromise Plasmodium falciparum mitochondrial function and show promising antimalarial activity. J. Med. Chem. 56 (2013) 6200-6215.
Sleebs B, Kersten W, Kulasegaram S, Nikolakopoulos G, Hatzis E, Moss R, Parisot J, Yang H, Czabotar P, Fairlie W, Lee E, Adams J, Chen L, van Delft M, Lowes K, Wei A, Huang D, Colman P, Street I, Baell J, Watson K, Lessene G. Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL. J. Med. Chem. 56 (2013) 5515-5540.
Dror RO, Green HF, Valant C, Borhani DW, Valcourt JR, Pan AC, Arlow DH, Canals M, Lane R, Rahmani R, Baell JB, Sexton PM, Christopoulos A, Shaw DE. Structural basis for modulation of a GPCR by allosteric drugs. Nature 503 (2013) 295-299.
Brady RM, Vom A, Roy MJ, Toovey N, Smith BJ, Moss RM, Hatzis E, Parisot JP, Yang H, Street IP, Colman PM, Czabotar PE, Baell JB*, Lessene G*. De-Novo Designed Library of Benzoylureas as Inhibitors of BCL-XL: Synthesis, Structural and Biochemical Characterization. J. Med. Chem. 57 (2014) 1323-1343.
Callaghan B, Kosari S, Pustovit R, Sartor DM, Ferens D, Ban K, Baell J, Nguyen TV, Rivera LR, Brock JA, Furness JB. Hypotensive effects of ghrelin receptor agonists mediated through a novel receptor. Br. J. Pharmacol. 171 (2014) 1275–1286.
Koehler MFT, Bergeron P, Choo EF, Lau K, Ndubaku C, Dudley D, Sleebs BE, Rye CS, Nikolakopoulos G, Bui C, Kulasegaram S, Kersten WJA, Smith BJ, Czabotar PE, Colman PM, Huang DCS, Baell JB, Watson KG, Hasvold L, Tao Z-F, Wang L, Souers AJ, Elmore SW, Flygare JA, Fairbrother WJ, Lessene G. Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL. ACS Med. Chem. Lett 5 (2014) 662-667.